This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumab (Cyramza)and pembrolizumab (Keytruda) works better than standard care practices. The main outcome that will be measured is the overall survival rates.
This study will take place in the United States.
There are a number of different treatments for non-small cell lung cancer (NSCLC). The standard type of treatment currently used works to kill cancer cells, stop cancer cells growing, and stop them from spreading. Ramucirumab and pembrolizumab are also anti-cancer drugs. They work in a slightly different way to the standard care drugs. Ramucirumab and pembrolizumab work by helping the body's immune system attack the cancer. It is not known if this type of treatment will work better than the standard in patients that have been treated before.
This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumaband pembrolizumab works better than standard care practices. The main outcome that will be measured is the overall survival rates.
Who are they looking for?
The study is recruiting 144 patients with advanced NSCLC. Patients must not have autoimmune diseases. Patients must not have experienced serious side effects on any other anti-cancer drugs. Patients must be otherwise healthy. Patients must not be breastfeeding or pregnant. Patients must have previously been treated with an anti-PD-L1 drug (such as pembrolizumab).
How will it work
The patients will be split up into two groups. The first group will receive standard care for NSCLC. The second group will receive treatment with ramucirumab and pembrolizumab for up to 35 cycles. Treatment will stop if the patient becomes too sick to continue.
Patients will be followed up for survival for up to 3 years.